Failure of a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of H. pylori Eradication in H. pylori-Infected Patients with Functional Dyspepsia

Background/Aims The role of Helicobacter pylori eradication in patients with functional dyspepsia (FD) is still uncertain. We originally planned a randomized clinical study to observe dyspeptic symptoms after H. pylori eradication therapy. However, we failed to complete the study; therefore, we analyzed the factors that affected the failure of the study. Methods Interviews and questionnaire surveys were conducted to analyze the factors that induced early termination from the study. Results Many patients were screened by gastroenterologists at 11 tertiary referral hospitals between July 2009 and August 2010; however, only 4 patients met the enrollment criteria. Most patients who visited our clinics had been experiencing FD symptoms for less than 6 months or were already taking medication. They also demanded to continue taking medications and using other drugs. Only 3 of the 4 patients signed informed consent. Conclusions The application of the current Rome III criteria to FD is difficult to evaluate in Korean patients with dyspeptic symptoms because of the early medical evaluation. Most Korean patients who were diagnosed with FD by the Rome III criteria did not overcome their fear of being unable to use rescue medications during the study period.

[1]  K. Tominaga,et al.  Prevalence of overlaps between GERD, FD and IBS and impact on health‐related quality of life , 2010, Journal of gastroenterology and hepatology.

[2]  H. Imamura,et al.  Clinical characteristics of Japanese dyspeptic patients: is the Rome III classification applicable? , 2010, Scandinavian journal of gastroenterology.

[3]  Hye-Kyung Jung,et al.  Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria , 2010, Journal of neurogastroenterology and motility.

[4]  R. Hunt,et al.  Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection , 2009, Journal of gastroenterology and hepatology.

[5]  J. Tack,et al.  Pathogenesis of Dyspepsia , 2008, Digestive Diseases.

[6]  Nayoung Kim,et al.  Seroprevalence of Helicobacter pylori in South Korea , 2007, Helicobacter.

[7]  T Rokkas,et al.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.

[8]  T. Piche A placebo-controlled trial of itopride in functional dyspepsia. , 2006 .

[9]  D. Drossman,et al.  The functional gastrointestinal disorders and the Rome III process. , 1999, Gastroenterology.

[10]  D. Forman,et al.  Eradication of Helicobacter pylori for non-ulcer dyspepsia. , 2006, The Cochrane database of systematic reviews.

[11]  J. Tack,et al.  Prevalence of acid reflux in functional dyspepsia and its association with symptom profile , 2005, Gut.

[12]  Myung-Gyu Choi,et al.  [The effect of mosapride on quality of life in functional dyspepsia]. , 2004, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[13]  M. Camilleri,et al.  Functional gastroduodenal disorders , 1999, Gut.